 Daniel Pollyea
Concepts (458)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 102 | 2023 | 532 | 25.090 |
Why?
| | Bridged Bicyclo Compounds, Heterocyclic | 30 | 2023 | 165 | 7.770 |
Why?
| | Myelodysplastic Syndromes | 27 | 2023 | 119 | 6.890 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 41 | 2023 | 1390 | 6.590 |
Why?
| | Sulfonamides | 26 | 2023 | 445 | 6.130 |
Why?
| | Azacitidine | 20 | 2023 | 119 | 5.280 |
Why?
| | Isocitrate Dehydrogenase | 13 | 2022 | 38 | 3.340 |
Why?
| | Hematologic Neoplasms | 10 | 2023 | 133 | 3.220 |
Why?
| | Antineoplastic Agents | 23 | 2023 | 1974 | 3.060 |
Why?
| | Mutation | 31 | 2023 | 3457 | 2.730 |
Why?
| | Neoplastic Stem Cells | 12 | 2023 | 336 | 2.340 |
Why?
| | Hematopoietic Stem Cell Transplantation | 15 | 2023 | 540 | 2.250 |
Why?
| | Triazines | 7 | 2021 | 39 | 2.180 |
Why?
| | Aminopyridines | 7 | 2021 | 85 | 2.110 |
Why?
| | Graft vs Host Disease | 8 | 2022 | 216 | 1.840 |
Why?
| | Remission Induction | 15 | 2021 | 247 | 1.720 |
Why?
| | Neoplasm, Residual | 6 | 2024 | 103 | 1.650 |
Why?
| | RNA Splicing Factors | 3 | 2020 | 50 | 1.600 |
Why?
| | Phosphoproteins | 3 | 2020 | 308 | 1.410 |
Why?
| | Humans | 144 | 2024 | 118972 | 1.380 |
Why?
| | Cytarabine | 8 | 2022 | 53 | 1.370 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2020 | 900 | 1.320 |
Why?
| | Leukemia | 4 | 2023 | 208 | 1.250 |
Why?
| | Aged | 53 | 2023 | 19657 | 1.210 |
Why?
| | Salvage Therapy | 5 | 2023 | 130 | 1.130 |
Why?
| | Clonal Evolution | 2 | 2017 | 26 | 1.110 |
Why?
| | Aged, 80 and over | 28 | 2021 | 6561 | 1.060 |
Why?
| | Prognosis | 23 | 2021 | 3443 | 1.040 |
Why?
| | Nuclear Proteins | 5 | 2018 | 597 | 1.000 |
Why?
| | Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2022 | 59 | 1.000 |
Why?
| | fms-Like Tyrosine Kinase 3 | 4 | 2017 | 42 | 0.990 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 3 | 2023 | 267 | 0.960 |
Why?
| | Carrier Proteins | 3 | 2017 | 726 | 0.910 |
Why?
| | Leukemia, Neutrophilic, Chronic | 3 | 2019 | 5 | 0.900 |
Why?
| | Drug Resistance, Neoplasm | 6 | 2020 | 671 | 0.900 |
Why?
| | Molecular Targeted Therapy | 6 | 2020 | 356 | 0.890 |
Why?
| | Spliceosomes | 2 | 2020 | 38 | 0.870 |
Why?
| | Dancing | 1 | 2022 | 15 | 0.860 |
Why?
| | Thrombocytopenia | 2 | 2023 | 185 | 0.860 |
Why?
| | Cord Blood Stem Cell Transplantation | 3 | 2020 | 96 | 0.850 |
Why?
| | Anemia | 2 | 2020 | 146 | 0.830 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 4 | 2018 | 226 | 0.830 |
Why?
| | Enzyme Inhibitors | 5 | 2020 | 827 | 0.800 |
Why?
| | Treatment Outcome | 27 | 2023 | 9342 | 0.800 |
Why?
| | Febrile Neutropenia | 1 | 2020 | 2 | 0.780 |
Why?
| | Splicing Factor U2AF | 2 | 2023 | 16 | 0.750 |
Why?
| | Serine-Arginine Splicing Factors | 2 | 2019 | 20 | 0.730 |
Why?
| | Receptors, Colony-Stimulating Factor | 2 | 2017 | 5 | 0.720 |
Why?
| | Middle Aged | 40 | 2022 | 27617 | 0.710 |
Why?
| | DNA Methylation | 3 | 2019 | 503 | 0.690 |
Why?
| | Transplantation Conditioning | 8 | 2022 | 156 | 0.690 |
Why?
| | Phenylurea Compounds | 7 | 2020 | 85 | 0.660 |
Why?
| | Staurosporine | 1 | 2017 | 23 | 0.640 |
Why?
| | Stem Cells | 3 | 2020 | 559 | 0.620 |
Why?
| | Benzimidazoles | 6 | 2020 | 140 | 0.610 |
Why?
| | Male | 49 | 2022 | 57801 | 0.580 |
Why?
| | Female | 54 | 2022 | 61564 | 0.580 |
Why?
| | Gene Frequency | 2 | 2017 | 513 | 0.570 |
Why?
| | Recurrence | 9 | 2023 | 975 | 0.570 |
Why?
| | Glycine | 4 | 2021 | 162 | 0.550 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2018 | 453 | 0.550 |
Why?
| | Monocytes | 2 | 2018 | 513 | 0.550 |
Why?
| | Neoplasms, Plasma Cell | 1 | 2015 | 6 | 0.550 |
Why?
| | Leukocytosis | 1 | 2015 | 34 | 0.550 |
Why?
| | Skin Neoplasms | 1 | 2023 | 762 | 0.540 |
Why?
| | Signal Transduction | 9 | 2022 | 4709 | 0.530 |
Why?
| | Epigenesis, Genetic | 1 | 2019 | 539 | 0.530 |
Why?
| | Gene Expression | 1 | 2020 | 1489 | 0.520 |
Why?
| | Computational Biology | 1 | 2019 | 588 | 0.510 |
Why?
| | Precision Medicine | 1 | 2018 | 363 | 0.510 |
Why?
| | Medical Oncology | 4 | 2023 | 229 | 0.500 |
Why?
| | Maximum Tolerated Dose | 5 | 2019 | 185 | 0.500 |
Why?
| | Patient Safety | 1 | 2018 | 281 | 0.500 |
Why?
| | Pyridines | 5 | 2023 | 440 | 0.500 |
Why?
| | Adult | 28 | 2023 | 31512 | 0.480 |
Why?
| | Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 | 2014 | 93 | 0.480 |
Why?
| | Hematopoiesis | 4 | 2020 | 175 | 0.480 |
Why?
| | Pyrazoles | 1 | 2017 | 363 | 0.470 |
Why?
| | Neoplasm Proteins | 4 | 2022 | 401 | 0.460 |
Why?
| | Immunity, Innate | 1 | 2019 | 745 | 0.450 |
Why?
| | Germ-Line Mutation | 3 | 2022 | 134 | 0.450 |
Why?
| | Retrospective Studies | 14 | 2023 | 12978 | 0.450 |
Why?
| | Oxidative Phosphorylation | 5 | 2022 | 156 | 0.440 |
Why?
| | Apoptosis | 4 | 2018 | 2484 | 0.440 |
Why?
| | Leukemia, Myeloid | 1 | 2012 | 42 | 0.440 |
Why?
| | Dose-Response Relationship, Drug | 7 | 2021 | 1945 | 0.440 |
Why?
| | Glutarates | 1 | 2012 | 6 | 0.440 |
Why?
| | DNA (Cytosine-5-)-Methyltransferases | 2 | 2018 | 27 | 0.430 |
Why?
| | Antibodies, Monoclonal, Humanized | 7 | 2023 | 667 | 0.420 |
Why?
| | Protein Kinase Inhibitors | 9 | 2018 | 811 | 0.410 |
Why?
| | RNA Splicing | 4 | 2023 | 243 | 0.410 |
Why?
| | Drug Delivery Systems | 1 | 2014 | 306 | 0.400 |
Why?
| | Neoplasms | 4 | 2018 | 2179 | 0.400 |
Why?
| | Follow-Up Studies | 8 | 2020 | 4596 | 0.400 |
Why?
| | Neutrophils | 2 | 2023 | 1233 | 0.400 |
Why?
| | United States Food and Drug Administration | 2 | 2022 | 175 | 0.390 |
Why?
| | Survival Rate | 10 | 2020 | 1720 | 0.370 |
Why?
| | Aldehyde Dehydrogenase | 3 | 2017 | 134 | 0.370 |
Why?
| | Rhipicephalus sanguineus | 1 | 2009 | 1 | 0.370 |
Why?
| | Triatoma | 1 | 2009 | 5 | 0.370 |
Why?
| | Wasps | 1 | 2009 | 8 | 0.370 |
Why?
| | Insect Bites and Stings | 1 | 2009 | 12 | 0.360 |
Why?
| | Syncope | 1 | 2009 | 32 | 0.360 |
Why?
| | Immunotherapy, Adoptive | 2 | 2022 | 191 | 0.340 |
Why?
| | Cytokines | 4 | 2020 | 1900 | 0.340 |
Why?
| | Electron Transport Complex II | 2 | 2019 | 24 | 0.340 |
Why?
| | Kaplan-Meier Estimate | 5 | 2020 | 842 | 0.330 |
Why?
| | Mutant Proteins | 2 | 2019 | 100 | 0.330 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2010 | 140 | 0.330 |
Why?
| | Cell Self Renewal | 2 | 2019 | 51 | 0.330 |
Why?
| | Administration, Oral | 4 | 2018 | 756 | 0.330 |
Why?
| | Proto-Oncogene Proteins | 2 | 2018 | 618 | 0.320 |
Why?
| | Bone Marrow | 4 | 2017 | 255 | 0.320 |
Why?
| | Transplantation, Homologous | 6 | 2022 | 415 | 0.310 |
Why?
| | Young Adult | 13 | 2021 | 10793 | 0.310 |
Why?
| | Gene Expression Regulation, Leukemic | 3 | 2016 | 49 | 0.310 |
Why?
| | Survival Analysis | 6 | 2020 | 1267 | 0.310 |
Why?
| | Drug Administration Schedule | 4 | 2020 | 736 | 0.300 |
Why?
| | Anaphylaxis | 1 | 2009 | 146 | 0.300 |
Why?
| | Disease-Free Survival | 5 | 2022 | 649 | 0.300 |
Why?
| | Acute Disease | 2 | 2023 | 940 | 0.280 |
Why?
| | Primary Myelofibrosis | 2 | 2016 | 9 | 0.280 |
Why?
| | Polycythemia Vera | 2 | 2016 | 13 | 0.280 |
Why?
| | Thrombocythemia, Essential | 2 | 2016 | 7 | 0.280 |
Why?
| | Clinical Trials as Topic | 4 | 2020 | 969 | 0.270 |
Why?
| | Hematopoietic Stem Cells | 3 | 2022 | 359 | 0.270 |
Why?
| | Biomarkers, Tumor | 4 | 2019 | 1059 | 0.260 |
Why?
| | DEAD-box RNA Helicases | 2 | 2015 | 56 | 0.260 |
Why?
| | Influenza Vaccines | 1 | 2010 | 500 | 0.260 |
Why?
| | Animals | 24 | 2023 | 33381 | 0.250 |
Why?
| | Influenza, Human | 1 | 2010 | 554 | 0.240 |
Why?
| | Stem Cell Transplantation | 3 | 2023 | 153 | 0.240 |
Why?
| | Induction Chemotherapy | 2 | 2021 | 59 | 0.240 |
Why?
| | Allografts | 2 | 2021 | 135 | 0.240 |
Why?
| | Antibodies, Monoclonal | 4 | 2017 | 1284 | 0.230 |
Why?
| | Finland | 1 | 2023 | 71 | 0.230 |
Why?
| | DNA-Binding Proteins | 1 | 2010 | 1346 | 0.230 |
Why?
| | DNA Mutational Analysis | 4 | 2019 | 381 | 0.230 |
Why?
| | Mice | 16 | 2023 | 15520 | 0.230 |
Why?
| | Drug Therapy, Combination | 4 | 2022 | 965 | 0.230 |
Why?
| | Antibodies, Neoplasm | 3 | 2007 | 30 | 0.220 |
Why?
| | RNA, Messenger | 1 | 2010 | 2657 | 0.220 |
Why?
| | Uncertainty | 1 | 2023 | 101 | 0.220 |
Why?
| | Disease Management | 4 | 2021 | 571 | 0.220 |
Why?
| | Proto-Oncogene Proteins c-myc | 2 | 2022 | 115 | 0.220 |
Why?
| | Interleukin-3 Receptor alpha Subunit | 2 | 2019 | 16 | 0.220 |
Why?
| | Hematology | 1 | 2022 | 12 | 0.210 |
Why?
| | Disease Progression | 3 | 2023 | 2490 | 0.210 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2023 | 72 | 0.210 |
Why?
| | Thalidomide | 2 | 2012 | 28 | 0.210 |
Why?
| | Amino Acid Transport System ASC | 1 | 2022 | 9 | 0.210 |
Why?
| | Myeloproliferative Disorders | 1 | 2022 | 26 | 0.210 |
Why?
| | Succinate Dehydrogenase | 2 | 2019 | 44 | 0.210 |
Why?
| | Minor Histocompatibility Antigens | 1 | 2022 | 41 | 0.210 |
Why?
| | Receptors, Mitogen | 1 | 2021 | 8 | 0.200 |
Why?
| | Lectins, C-Type | 1 | 2021 | 63 | 0.200 |
Why?
| | Erythroblasts | 1 | 2020 | 12 | 0.200 |
Why?
| | Blood Cell Count | 1 | 2020 | 53 | 0.190 |
Why?
| | Cell Transformation, Neoplastic | 3 | 2018 | 317 | 0.190 |
Why?
| | Lipase | 1 | 2020 | 70 | 0.190 |
Why?
| | STAT3 Transcription Factor | 1 | 2022 | 189 | 0.180 |
Why?
| | Histocompatibility Testing | 2 | 2019 | 123 | 0.180 |
Why?
| | Inflammation Mediators | 2 | 2020 | 502 | 0.180 |
Why?
| | Tumor Lysis Syndrome | 1 | 2019 | 10 | 0.180 |
Why?
| | Immunoconjugates | 1 | 2021 | 89 | 0.180 |
Why?
| | Dendritic Cells | 1 | 2023 | 442 | 0.180 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2021 | 136 | 0.180 |
Why?
| | Leukopoiesis | 1 | 2019 | 10 | 0.170 |
Why?
| | United States | 5 | 2023 | 12555 | 0.170 |
Why?
| | Genetic Testing | 2 | 2019 | 389 | 0.170 |
Why?
| | Myeloid Progenitor Cells | 1 | 2019 | 16 | 0.170 |
Why?
| | Fatty Acids | 2 | 2020 | 407 | 0.170 |
Why?
| | NADPH Oxidase 2 | 1 | 2019 | 42 | 0.170 |
Why?
| | NF-kappa B p50 Subunit | 1 | 2019 | 26 | 0.170 |
Why?
| | Age Factors | 5 | 2022 | 2995 | 0.170 |
Why?
| | Mycoses | 1 | 2019 | 69 | 0.170 |
Why?
| | RAW 264.7 Cells | 1 | 2019 | 42 | 0.170 |
Why?
| | K562 Cells | 1 | 2019 | 73 | 0.170 |
Why?
| | Tricarboxylic Acids | 1 | 2018 | 11 | 0.170 |
Why?
| | Genomics | 3 | 2019 | 706 | 0.170 |
Why?
| | Ketoglutaric Acids | 1 | 2018 | 16 | 0.170 |
Why?
| | Mitochondrial Proteins | 2 | 2018 | 226 | 0.170 |
Why?
| | Hematologic Diseases | 1 | 2019 | 60 | 0.170 |
Why?
| | Antibiotic Prophylaxis | 1 | 2019 | 100 | 0.170 |
Why?
| | Antibodies | 1 | 2021 | 392 | 0.170 |
Why?
| | Amino Acids | 2 | 2020 | 464 | 0.160 |
Why?
| | Thiotepa | 1 | 2018 | 19 | 0.160 |
Why?
| | Antimetabolites, Antineoplastic | 1 | 2018 | 83 | 0.160 |
Why?
| | Lymphoma | 2 | 2017 | 180 | 0.160 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2020 | 1244 | 0.160 |
Why?
| | Trees | 1 | 2018 | 67 | 0.160 |
Why?
| | Cysteine | 1 | 2019 | 184 | 0.160 |
Why?
| | Fusion Proteins, bcr-abl | 2 | 2014 | 61 | 0.150 |
Why?
| | Mediastinal Neoplasms | 1 | 2017 | 35 | 0.150 |
Why?
| | Hematinics | 1 | 2017 | 17 | 0.150 |
Why?
| | Confidence Intervals | 1 | 2018 | 324 | 0.150 |
Why?
| | HLA-DR Antigens | 1 | 2018 | 224 | 0.150 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2018 | 178 | 0.150 |
Why?
| | Infusions, Intravenous | 1 | 2018 | 380 | 0.150 |
Why?
| | Periodicals as Topic | 1 | 2019 | 191 | 0.150 |
Why?
| | Hedgehog Proteins | 1 | 2018 | 175 | 0.140 |
Why?
| | Ataxia Telangiectasia Mutated Proteins | 1 | 2016 | 62 | 0.140 |
Why?
| | Energy Metabolism | 2 | 2019 | 767 | 0.140 |
Why?
| | Pyrimidines | 2 | 2017 | 382 | 0.140 |
Why?
| | Cohort Studies | 5 | 2022 | 5116 | 0.140 |
Why?
| | Glucosephosphate Dehydrogenase | 1 | 2016 | 41 | 0.140 |
Why?
| | Unrelated Donors | 1 | 2016 | 38 | 0.140 |
Why?
| | Leukocyte Count | 1 | 2017 | 305 | 0.140 |
Why?
| | Nitriles | 1 | 2017 | 155 | 0.140 |
Why?
| | Genome, Human | 1 | 2018 | 387 | 0.140 |
Why?
| | Geriatric Assessment | 1 | 2018 | 185 | 0.140 |
Why?
| | Biomarkers | 3 | 2022 | 3588 | 0.140 |
Why?
| | Oncogene Proteins | 1 | 2016 | 52 | 0.140 |
Why?
| | Electronic Health Records | 1 | 2023 | 829 | 0.140 |
Why?
| | NF-E2-Related Factor 2 | 1 | 2016 | 83 | 0.140 |
Why?
| | Methyltransferases | 1 | 2016 | 61 | 0.130 |
Why?
| | Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 19 | 0.130 |
Why?
| | Mice, Inbred NOD | 4 | 2019 | 574 | 0.130 |
Why?
| | Programmed Cell Death 1 Receptor | 1 | 2017 | 197 | 0.130 |
Why?
| | Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 64 | 0.130 |
Why?
| | Lipopolysaccharides | 1 | 2019 | 870 | 0.130 |
Why?
| | Chromosome Aberrations | 1 | 2015 | 136 | 0.130 |
Why?
| | Hemoglobins | 2 | 2018 | 326 | 0.130 |
Why?
| | Genetic Predisposition to Disease | 2 | 2022 | 2275 | 0.130 |
Why?
| | Oligomycins | 1 | 2014 | 8 | 0.130 |
Why?
| | Mitochondria | 2 | 2018 | 786 | 0.130 |
Why?
| | Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 18 | 0.130 |
Why?
| | T-Lymphocytes | 1 | 2022 | 1774 | 0.130 |
Why?
| | Histone-Lysine N-Methyltransferase | 1 | 2016 | 99 | 0.130 |
Why?
| | Homeostasis | 1 | 2018 | 594 | 0.130 |
Why?
| | In Situ Hybridization, Fluorescence | 1 | 2015 | 310 | 0.120 |
Why?
| | Cell Survival | 4 | 2022 | 1047 | 0.120 |
Why?
| | Necrosis | 1 | 2015 | 230 | 0.120 |
Why?
| | Calcineurin Inhibitors | 1 | 2014 | 61 | 0.120 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 1868 | 0.120 |
Why?
| | Adolescent | 6 | 2019 | 18480 | 0.120 |
Why?
| | Vidarabine | 2 | 2018 | 27 | 0.120 |
Why?
| | Harringtonines | 1 | 2013 | 2 | 0.120 |
Why?
| | Tumor Suppressor Proteins | 1 | 2016 | 289 | 0.120 |
Why?
| | Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2013 | 1 | 0.120 |
Why?
| | Cells, Cultured | 5 | 2019 | 4077 | 0.120 |
Why?
| | Alemtuzumab | 3 | 2007 | 12 | 0.120 |
Why?
| | Registries | 2 | 2023 | 1810 | 0.110 |
Why?
| | Phenotype | 2 | 2019 | 3003 | 0.110 |
Why?
| | Gene Expression Profiling | 3 | 2019 | 1597 | 0.110 |
Why?
| | Glucose | 1 | 2018 | 953 | 0.110 |
Why?
| | Carbon Monoxide | 1 | 2013 | 64 | 0.110 |
Why?
| | Gene Expression Regulation, Neoplastic | 1 | 2018 | 1167 | 0.110 |
Why?
| | Pyridazines | 1 | 2013 | 50 | 0.110 |
Why?
| | Nausea | 1 | 2012 | 107 | 0.110 |
Why?
| | 5-Methylcytosine | 1 | 2012 | 16 | 0.110 |
Why?
| | Interleukin-1 | 1 | 2017 | 980 | 0.110 |
Why?
| | Liver | 1 | 2020 | 1816 | 0.110 |
Why?
| | Vomiting | 1 | 2012 | 123 | 0.110 |
Why?
| | Membrane Proteins | 1 | 2018 | 1055 | 0.100 |
Why?
| | Imidazoles | 1 | 2013 | 232 | 0.100 |
Why?
| | Biopsy | 1 | 2015 | 1079 | 0.100 |
Why?
| | Length of Stay | 1 | 2016 | 1032 | 0.100 |
Why?
| | Incidence | 2 | 2016 | 2424 | 0.100 |
Why?
| | Core Binding Factor Alpha 2 Subunit | 2 | 2023 | 30 | 0.100 |
Why?
| | Software | 1 | 2015 | 613 | 0.100 |
Why?
| | Fatigue | 1 | 2012 | 297 | 0.100 |
Why?
| | Dioxygenases | 1 | 2010 | 26 | 0.100 |
Why?
| | Amino Acid Sequence | 2 | 2015 | 2071 | 0.090 |
Why?
| | Sesquiterpenes | 2 | 2016 | 51 | 0.090 |
Why?
| | Cell Line, Tumor | 5 | 2018 | 2851 | 0.090 |
Why?
| | Oxidants | 1 | 2011 | 122 | 0.090 |
Why?
| | GTP-Binding Proteins | 1 | 2011 | 147 | 0.090 |
Why?
| | Ethanol | 1 | 2015 | 575 | 0.090 |
Why?
| | Chronic Disease | 1 | 2016 | 1636 | 0.090 |
Why?
| | Wasp Venoms | 1 | 2009 | 4 | 0.090 |
Why?
| | Insulin Resistance | 1 | 2018 | 1180 | 0.090 |
Why?
| | Protein Multimerization | 1 | 2011 | 161 | 0.090 |
Why?
| | Injections, Subcutaneous | 1 | 2009 | 138 | 0.090 |
Why?
| | Hydrogen Peroxide | 1 | 2011 | 305 | 0.090 |
Why?
| | Mice, Transgenic | 3 | 2023 | 2025 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2010 | 207 | 0.080 |
Why?
| | Emergencies | 1 | 2009 | 153 | 0.080 |
Why?
| | Immunization Schedule | 1 | 2010 | 188 | 0.080 |
Why?
| | Epinephrine | 1 | 2009 | 167 | 0.080 |
Why?
| | RNA, Small Interfering | 3 | 2016 | 564 | 0.080 |
Why?
| | Inflammation | 1 | 2019 | 2566 | 0.080 |
Why?
| | Melphalan | 1 | 2007 | 30 | 0.080 |
Why?
| | Mice, Inbred C57BL | 4 | 2020 | 4908 | 0.080 |
Why?
| | Blood Transfusion | 2 | 2020 | 306 | 0.080 |
Why?
| | Transplantation Chimera | 1 | 2007 | 51 | 0.080 |
Why?
| | Tumor Cells, Cultured | 2 | 2022 | 874 | 0.070 |
Why?
| | HEK293 Cells | 2 | 2019 | 625 | 0.070 |
Why?
| | Karnofsky Performance Status | 1 | 2006 | 36 | 0.070 |
Why?
| | Receptors, Thrombopoietin | 2 | 2016 | 7 | 0.070 |
Why?
| | Calreticulin | 2 | 2016 | 24 | 0.070 |
Why?
| | Ganciclovir | 1 | 2006 | 46 | 0.070 |
Why?
| | Janus Kinase 2 | 2 | 2016 | 32 | 0.070 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2014 | 407 | 0.070 |
Why?
| | Exome | 2 | 2018 | 220 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2010 | 693 | 0.070 |
Why?
| | Valine | 1 | 2006 | 77 | 0.070 |
Why?
| | Risk Assessment | 3 | 2021 | 3057 | 0.070 |
Why?
| | Risk Factors | 3 | 2014 | 9000 | 0.070 |
Why?
| | Acyclovir | 1 | 2006 | 105 | 0.070 |
Why?
| | Philadelphia Chromosome | 2 | 2016 | 15 | 0.070 |
Why?
| | Cell Proliferation | 3 | 2020 | 2275 | 0.060 |
Why?
| | Oxidation-Reduction | 2 | 2019 | 940 | 0.060 |
Why?
| | Bone Marrow Transplantation | 1 | 2006 | 244 | 0.060 |
Why?
| | Janus Kinases | 2 | 2015 | 14 | 0.060 |
Why?
| | Pedigree | 2 | 2015 | 485 | 0.060 |
Why?
| | Diamines | 1 | 2023 | 3 | 0.060 |
Why?
| | Cytomegalovirus Infections | 1 | 2006 | 187 | 0.060 |
Why?
| | Antigens, CD34 | 1 | 2023 | 98 | 0.060 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2016 | 740 | 0.060 |
Why?
| | Breast Neoplasms | 1 | 2015 | 1965 | 0.060 |
Why?
| | Flow Cytometry | 2 | 2018 | 1085 | 0.060 |
Why?
| | Chemotaxis | 1 | 2023 | 137 | 0.060 |
Why?
| | Angiogenesis Inhibitors | 1 | 2004 | 219 | 0.050 |
Why?
| | Practice Guidelines as Topic | 1 | 2010 | 1440 | 0.050 |
Why?
| | Neutropenia | 1 | 2022 | 133 | 0.050 |
Why?
| | Drug Interactions | 2 | 2013 | 352 | 0.050 |
Why?
| | Early Termination of Clinical Trials | 1 | 2021 | 15 | 0.050 |
Why?
| | Quinuclidines | 1 | 2020 | 4 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2020 | 57 | 0.050 |
Why?
| | Hyperbilirubinemia | 1 | 2020 | 16 | 0.050 |
Why?
| | Receptors, Cell Surface | 1 | 2022 | 367 | 0.050 |
Why?
| | Niacinamide | 1 | 2020 | 70 | 0.050 |
Why?
| | Antiviral Agents | 1 | 2006 | 654 | 0.050 |
Why?
| | Neoplasms, Second Primary | 1 | 2021 | 93 | 0.050 |
Why?
| | Proportional Hazards Models | 2 | 2017 | 1125 | 0.040 |
Why?
| | Cytogenetic Analysis | 1 | 2019 | 28 | 0.040 |
Why?
| | Multicenter Studies as Topic | 1 | 2020 | 253 | 0.040 |
Why?
| | Lentivirus | 1 | 2019 | 52 | 0.040 |
Why?
| | Iron | 1 | 2020 | 248 | 0.040 |
Why?
| | Daunorubicin | 1 | 2018 | 23 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2016 | 2680 | 0.040 |
Why?
| | Consolidation Chemotherapy | 1 | 2018 | 8 | 0.040 |
Why?
| | Disease Susceptibility | 1 | 2021 | 331 | 0.040 |
Why?
| | Mice, Nude | 2 | 2015 | 663 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2018 | 23 | 0.040 |
Why?
| | Drug Monitoring | 1 | 2020 | 187 | 0.040 |
Why?
| | Myeloablative Agonists | 1 | 2018 | 22 | 0.040 |
Why?
| | Mice, SCID | 1 | 2019 | 333 | 0.040 |
Why?
| | Fetal Blood | 1 | 2020 | 272 | 0.040 |
Why?
| | Datasets as Topic | 1 | 2018 | 103 | 0.040 |
Why?
| | Cause of Death | 1 | 2020 | 380 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 278 | 0.040 |
Why?
| | Disease Models, Animal | 2 | 2020 | 3730 | 0.040 |
Why?
| | Forkhead Transcription Factors | 1 | 2019 | 182 | 0.040 |
Why?
| | Whole-Body Irradiation | 1 | 2018 | 72 | 0.040 |
Why?
| | HLA Antigens | 1 | 2019 | 230 | 0.040 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2020 | 156 | 0.040 |
Why?
| | Receptors, Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2017 | 13 | 0.040 |
Why?
| | Cell Count | 1 | 2018 | 315 | 0.040 |
Why?
| | Biological Transport | 1 | 2018 | 382 | 0.040 |
Why?
| | Glutathione | 1 | 2019 | 324 | 0.040 |
Why?
| | Tumor Microenvironment | 1 | 2020 | 454 | 0.040 |
Why?
| | Tumor Stem Cell Assay | 1 | 2017 | 35 | 0.040 |
Why?
| | Glycolysis | 1 | 2018 | 224 | 0.040 |
Why?
| | Retinal Dehydrogenase | 1 | 2017 | 40 | 0.040 |
Why?
| | Combined Modality Therapy | 1 | 2020 | 1166 | 0.040 |
Why?
| | Arsenicals | 1 | 2017 | 26 | 0.040 |
Why?
| | Adenosine Triphosphate | 1 | 2019 | 439 | 0.040 |
Why?
| | Oxides | 1 | 2017 | 42 | 0.040 |
Why?
| | Diet, High-Fat | 1 | 2018 | 247 | 0.040 |
Why?
| | Health Services Accessibility | 1 | 2023 | 781 | 0.040 |
Why?
| | Benzothiazoles | 1 | 2016 | 37 | 0.040 |
Why?
| | Hydrazines | 1 | 2016 | 31 | 0.040 |
Why?
| | Transcriptome | 1 | 2022 | 756 | 0.040 |
Why?
| | NADP | 1 | 2016 | 50 | 0.040 |
Why?
| | Cyclophosphamide | 1 | 2017 | 222 | 0.040 |
Why?
| | Heterografts | 1 | 2017 | 130 | 0.040 |
Why?
| | Deoxyglucose | 1 | 2016 | 46 | 0.040 |
Why?
| | Reactive Oxygen Species | 1 | 2019 | 576 | 0.040 |
Why?
| | Drug Combinations | 1 | 2017 | 291 | 0.040 |
Why?
| | Myeloid Ecotropic Viral Integration Site 1 Protein | 1 | 2016 | 12 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 409 | 0.030 |
Why?
| | Sample Size | 1 | 2016 | 133 | 0.030 |
Why?
| | Kinetics | 1 | 2019 | 1624 | 0.030 |
Why?
| | Receptors, Interleukin-1 | 1 | 2017 | 228 | 0.030 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2017 | 285 | 0.030 |
Why?
| | Isoenzymes | 1 | 2016 | 297 | 0.030 |
Why?
| | Quality of Life | 2 | 2016 | 2366 | 0.030 |
Why?
| | Positron-Emission Tomography | 1 | 2017 | 298 | 0.030 |
Why?
| | Metabolome | 1 | 2018 | 296 | 0.030 |
Why?
| | Splenomegaly | 1 | 2015 | 17 | 0.030 |
Why?
| | Repressor Proteins | 1 | 2018 | 377 | 0.030 |
Why?
| | Lipid Metabolism | 1 | 2018 | 477 | 0.030 |
Why?
| | Phosphatidylinositol 3-Kinases | 1 | 2017 | 341 | 0.030 |
Why?
| | Hydroxyurea | 1 | 2015 | 30 | 0.030 |
Why?
| | Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
| | Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
| | Sirolimus | 1 | 2016 | 195 | 0.030 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2017 | 369 | 0.030 |
Why?
| | Comorbidity | 2 | 2013 | 1527 | 0.030 |
Why?
| | Diagnosis, Differential | 1 | 2019 | 1384 | 0.030 |
Why?
| | Membrane Potential, Mitochondrial | 1 | 2014 | 56 | 0.030 |
Why?
| | Imatinib Mesylate | 1 | 2014 | 64 | 0.030 |
Why?
| | Fluorescent Antibody Technique | 1 | 2015 | 410 | 0.030 |
Why?
| | Cell Differentiation | 1 | 2022 | 1753 | 0.030 |
Why?
| | Interleukin-1beta | 1 | 2017 | 379 | 0.030 |
Why?
| | Immunologic Factors | 1 | 2017 | 225 | 0.030 |
Why?
| | Sequence Homology, Amino Acid | 1 | 2015 | 372 | 0.030 |
Why?
| | Dasatinib | 1 | 2014 | 46 | 0.030 |
Why?
| | Age of Onset | 1 | 2015 | 467 | 0.030 |
Why?
| | Superoxides | 1 | 2014 | 221 | 0.030 |
Why?
| | Structure-Activity Relationship | 1 | 2015 | 522 | 0.030 |
Why?
| | Genetic Heterogeneity | 1 | 2014 | 56 | 0.030 |
Why?
| | Thiazoles | 1 | 2014 | 121 | 0.030 |
Why?
| | Research Design | 1 | 2020 | 969 | 0.030 |
Why?
| | Cyclosporine | 1 | 2014 | 173 | 0.030 |
Why?
| | Leukemia, Lymphoid | 1 | 2013 | 27 | 0.030 |
Why?
| | Drug Synergism | 1 | 2014 | 339 | 0.030 |
Why?
| | Trans-Activators | 1 | 2016 | 373 | 0.030 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 58 | 0.030 |
Why?
| | Up-Regulation | 1 | 2016 | 872 | 0.030 |
Why?
| | RNA Interference | 1 | 2014 | 460 | 0.030 |
Why?
| | Phosphorylation | 1 | 2017 | 1633 | 0.030 |
Why?
| | Homeodomain Proteins | 1 | 2016 | 468 | 0.030 |
Why?
| | Mice, Inbred BALB C | 1 | 2015 | 1206 | 0.030 |
Why?
| | Cost-Benefit Analysis | 1 | 2015 | 554 | 0.030 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2020 | 2062 | 0.030 |
Why?
| | Thrombosis | 1 | 2015 | 309 | 0.030 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 526 | 0.020 |
Why?
| | Leupeptins | 1 | 2011 | 10 | 0.020 |
Why?
| | HL-60 Cells | 1 | 2011 | 29 | 0.020 |
Why?
| | Blast Crisis | 1 | 2011 | 19 | 0.020 |
Why?
| | Cysteine Proteinase Inhibitors | 1 | 2011 | 50 | 0.020 |
Why?
| | Proteasome Inhibitors | 1 | 2011 | 44 | 0.020 |
Why?
| | Mitoxantrone | 1 | 2010 | 12 | 0.020 |
Why?
| | Free Radical Scavengers | 1 | 2011 | 88 | 0.020 |
Why?
| | Child | 1 | 2010 | 19129 | 0.020 |
Why?
| | Prospective Studies | 2 | 2016 | 6471 | 0.020 |
Why?
| | Etoposide | 1 | 2010 | 149 | 0.020 |
Why?
| | Proteasome Endopeptidase Complex | 1 | 2011 | 139 | 0.020 |
Why?
| | Genotype | 1 | 2015 | 1882 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2326 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2015 | 2871 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2011 | 158 | 0.020 |
Why?
| | Acetylcysteine | 1 | 2011 | 148 | 0.020 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2011 | 363 | 0.020 |
Why?
| | Treatment Failure | 1 | 2010 | 341 | 0.020 |
Why?
| | Models, Biological | 1 | 2017 | 1715 | 0.020 |
Why?
| | Insulin | 1 | 2018 | 2162 | 0.020 |
Why?
| | RNA-Binding Proteins | 1 | 2011 | 371 | 0.020 |
Why?
| | Nitroimidazoles | 1 | 2004 | 6 | 0.020 |
Why?
| | Cyclohexanes | 1 | 2004 | 22 | 0.020 |
Why?
| | Fluorescein | 1 | 2004 | 27 | 0.020 |
Why?
| | In Situ Nick-End Labeling | 1 | 2004 | 124 | 0.020 |
Why?
| | Radiation-Sensitizing Agents | 1 | 2004 | 38 | 0.020 |
Why?
| | Lectins | 1 | 2004 | 50 | 0.020 |
Why?
| | Capillaries | 1 | 2004 | 103 | 0.010 |
Why?
| | Neoplasm Transplantation | 1 | 2004 | 245 | 0.010 |
Why?
| | In Situ Hybridization | 1 | 2004 | 311 | 0.010 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2004 | 114 | 0.010 |
Why?
| | Microcirculation | 1 | 2004 | 155 | 0.010 |
Why?
| | Angiography | 1 | 2004 | 185 | 0.010 |
Why?
| | Wilms Tumor | 1 | 2004 | 69 | 0.010 |
Why?
| | Neovascularization, Pathologic | 1 | 2004 | 287 | 0.010 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2004 | 527 | 0.010 |
Why?
| | Immunohistochemistry | 1 | 2004 | 1691 | 0.010 |
Why?
| | Hypoxia | 1 | 2004 | 963 | 0.010 |
Why?
|
|
Pollyea's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|